Overview

1977 Cover of Nature Magazine

Nature, December 1977, highlights Dr. Paul Bottomley and colleagues' ground-breaking work in "Zeugmatography", later known as MRI.

Reprinted by permission from Macmillan Publishers Ltd: Nature Magazine (Vol. 270 No. 5638) Copyright 1977

Our mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep-brain stimulation, and biopsy, with future applications of laser ablation, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked and is installed in 60 active clinical sites in the United States. The Company’s SmartFlow® cannula is being used in partnership or evaluation with more than 20 individual biologics and drug delivery companies in various stages from preclinical research to late stage regulatory trials. To date, more than 3,500 cases have been performed and supported by the Company’s field-based clinical support team which offers support and services for our partners.

We have two product platforms. Our ClearPoint® system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. Our ClearTrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. Both systems utilize intra-procedural magnetic resonance imaging to guide the procedures. Both systems are designed to work in a hospital’s existing MRI suite.

Our products are designed to provide a new, minimally invasive surgical approach for the benefit of large patient populations. Our ClearPoint system is designed to enable the delivery of therapies to treat certain neurological diseases. Our ClearTrace system is designed to deliver therapies to treat certain cardiac diseases. We believe that our two product platforms, subject to appropriate regulatory clearance and approval, will provide better patient outcomes, enable physicians and hospitals to treat more patients, and reduce costs to the healthcare system.

Advancing Patient Care.  Our product platforms are designed to enable physicians to see the target site, guide the surgical instrument to the site, deliver the therapy, monitor for adverse events and complications and confirm the desired results of the procedure, all under high resolution, intra-procedural magnetic resonance imaging. 

Providing Care for More Patients. We believe that our ClearPoint system may enable physicians to treat patients who otherwise may not be treated utilizing current surgical techniques.  In addition, by providing direct, intra-procedural visualization, we believe our ClearPoint system could reduce the amount of time needed to perform procedures and enable physicians to treat more patients in a given period of time.

Improving Utilization of Resources. We believe that use of our products may result in more efficient utilization of healthcare resources and physician time. Our product platforms are designed to work in a hospital’s existing MRI suite, which adds additional utility for an infrastructure investment that has already been made by the hospital. Further, we believe our intra-procedural visualization capabilities and streamlined workflows may increase procedure efficiencies.